UBM — Ulisse Biomed Spa Income Statement
0.000.00%
Last trade - 00:00
- €28.67m
- €25.78m
- €0.14m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.011 | 0.429 | 0.277 | 0.138 |
Cost of Revenue | |||||
Gross Profit | -0.701 | -0.697 | 0.2 | -0.269 | -0.895 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.65 | 1.13 | 0.204 | 0.88 | 1.44 |
Operating Profit | -1.65 | -1.12 | 0.224 | -0.603 | -1.31 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.93 | -1.12 | 0.224 | -0.604 | -1.31 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.93 | -1.1 | 0.222 | -0.604 | -1.31 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.93 | -1.1 | 0.222 | -0.604 | -1.31 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.93 | -1.1 | 0.222 | -0.604 | -1.31 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.24 | -0.136 | 0.028 | -0.075 | -0.162 |